WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

EMA

The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.

www.ema.europa.eu

EMA RSS Channel

Filters
List of articles in category EMA
Title Published Date
EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice 31 March 2022
EMA: Human medicines highlights of 2021 18 February 2022
ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines 06 September 2021
AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 07 April 2021
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna 29 March 2021
EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events 15 March 2021
EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU 11 March 2021
EMA starts rolling review of the Sputnik V COVID-19 vaccine 08 March 2021
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca 12 January 2021
Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application 15 December 2020
EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2 01 December 2020
EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine 01 December 2020
EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation 30 September 2020
Global regulators commit to cooperate on observational research in the context of COVID-19 21 May 2020
First vaccine to protect against Ebola 28 October 2019
EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US 29 August 2019
EMA to relocate to Amsterdam, the Netherlands 22 November 2017
Green light given for new EudraVigilance system for collection and monitoring of suspected adverse reactions 29 May 2017
Launch of PRIME - Paving the way for promising medicines for patients 10 March 2016
Human medicines: highlights of 2015 22 January 2016
  • Start
  • Prev
  • 1
  • 2
  • 3
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
  • Research identifies, exploits vulnerability in certain high-risk cancers
  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. EMA
  4. EMEA recommends suspension of the marketing authorisation of Raptiva (efalizumab)

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.